Home
Global Biopharmaceutical Company - Br...

十一月 2025的Global Biopharmaceutical...市场份额分析

Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.

健康 > 生物科技及制药

域bmsfrance.fr

成立年份--

员工501 - 1000

年营收--

Global Biopharmaceutical Company - Br...

Global Biopharmaceutical Company - Br...（包含公司地区分支机构）

bmsfrance.fr

查看更多网站流量和参与度信息

Global Biopharmaceutical Company - Br...热门域名的总访问量

了解Global Biopharmaceutical Company - Br...市场份额和潜在市场覆盖范围。

过去 3 个月的总访问量

无数据可显示

Global Biopharmaceutical Company - Br...热门域名的平均访问时长

分析Global Biopharmaceutical Company - Br...参与度指标。

过去 3 个月的平均访问时长

无数据可显示

Global Biopharmaceutical Company - Br...热门域名的平均页面浏览量

了解Global Biopharmaceutical Company - Br...如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。

过去 3 个月的平均页面浏览量

无数据可显示

Global Biopharmaceutical Company - Br... 排名靠前的竞争对手（按域名）

十一月 2025的热门相似网站，按亲和力排名

boehringer-ingelheim.fr公司名称Boehringer Ingelheim员工> 10001总部德国, Ingelheim am Rhein年营收> $1B总访问量--健康 > 生物科技及制药

Global Biopharmaceutical Company - Br... 采用的主要技术

这些是排名前 Global Biopharmaceutical Company - Br... 的顶级域名所使用的网站技术（按行业分列）

付费广告 (7)

DoubleClick

转化和分析 (5)

DoubleClick Floodlight

社交 (5)

Instagram

视听媒体 (2)

YouTube

更多技术

7

查看全部

Global Biopharmaceutical Company - Br... 的新闻与信号

借助 Similarweb 销售信号提醒，每当在目标受众之中出现新的机会或威胁时，您都会收到所识别出购买信号的每日更新。

新闻Bmsfrance acquired Myokardia for $13B on Oct 12th '20.Bristol-Myers Squibb said on Monday it would buy MyoKardia for about $13 billion to bolster its portfolio of heart disease treatments, as it seeks to reduce some of its dependence on cancer drugs.

新闻Bmsfrance acquired Celgene Corp. for $74B on Jan 1st '19.REUTERS/Regis Duvignau/File Photo New York-based Bristol-Myers bought Celgene for more than $74 billion in a deal announced last January.

新闻Domain Therapeutics SA partnered with Bmsfrance on Feb 27th '18.Domain Therapeutics, a France- and Quebec-based biopharmaceutical company that specializes in the research and development of new drug candidates that target transmembrane receptors, today announces the signing of a licensing agreement for its bioSens-All™ technology with Bristol-Myers Squibb, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.